Luisa B. Tedesco
Rio Grande, RS, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Thirty-three years of X-linked adrenoleukodystrophy diagnosis at a Brazilian reference center: diagnostic patterns and key findings.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: July 23, 2026
Renal tubular injury and inflammation in patients with methylmalonic and propionic acidemias: the role of β2-microglobulin.
Journal: Archives of biochemistry and biophysics
Published: July 22, 2026
Protective in vitro effects of antioxidants against DNA damage induced by metabolites accumulated in propionic and methylmalonic acidemias.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: May 22, 2026
Deleterious in vitro effects of ammonia and accumulated urea cycle amino acids on leukocyte DNA: assessment of the antioxidant effects of N-acetylcysteine and L-carnitine.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: February 10, 2026
Oxidative Stress and Inflammation in Methylmalonic and Propionic Acidemias: A Review.
Journal: Cell biochemistry and function
Published: January 10, 2026
Toxicity of Organic Acids Leading to Renal Dysfunction in Glutaric Acidemia Type I: A Mini Review.
Journal: Cell biochemistry and function
Published: December 28, 2025
Evaluation of c26:0-Lyso-Phosphatidylcholine Levels in X-Linked Adrenoleukodystrophy: Diagnosis and Biochemical Monitoring.
Journal: International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
Published: December 09, 2025
Inflammation in maple syrup urine disease.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: October 29, 2025
Neuroprotective, antioxidant and anti-inflammatory effect of carnitine in patients with Maple syrup urine disease: branched-chain amino acids and branched-chain keto acids levels.
Journal: Metabolic brain disease
Published: February 07, 2025
Nitisinone treatment protect hereditary tyrosinemia type I patients against inflammation, DNA and protein oxidative damage by decreasing succinylacetone levels.
Journal: Metabolic brain disease
Published: February 06, 2025
Showing 1-10 of 10
Last Updated: 09/26/2026